Cytogenetic and molecular response categories according to TKI modality at 3 and 6 mo (among evaluable patients for which corresponding values were available)
| 3- and 6-mo response categories . | Response, n (%) . | |||||
|---|---|---|---|---|---|---|
| Imatinib 400 . | Imatinib 800 . | Imatinib (400 and 800) . | Nilotinib . | Dasatinib . | Overall . | |
| 3-mo cytogenetic response (n = 448) | ||||||
| 0 | 25 (37) | 118 (62) | 143 (55) | 79 (84) | 78 (81) | 300 (67) |
| 35 < 0 | 24 (35) | 55 (29) | 79 (30) | 12 (13) | 13 (13) | 104 (23) |
| >35 | 18 (26) | 18 (9) | 36 (14) | 3 (3) | 5 (5) | 44 (10) |
| 3-mo molecular response (n = 379) | ||||||
| ≤1 | 12 (70) | 133 (78) | 145 (77) | 79 (8) | 76 (79) | 300 (79) |
| >1-10 | 4 (23) | 32 (19) | 36 (19) | 16 (16) | 14 (14) | 66 (17) |
| >10 | 1 (6) | 5 (3) | 6 (3) | 1 (1) | 6 (6) | 13 (3) |
| 6-mo cytogenetic response (n = 424) | ||||||
| 0 | 29 (43) | 154 (84) | 183 (73) | 85 (96) | 79 (91) | 347 (81) |
| 35 < 0 | 27 (40) | 21 (11) | 48 (19) | — | 5 (6) | 53 (12) |
| >35 | 11 (16) | 7 (4) | 18 (7) | 3 (3) | 3 (3) | 24 (7) |
| 6-mo molecular response (n = 360) | ||||||
| ≤1 | 3 (60) | 156 (89) | 159 (88) | 81 (91) | 81 (89) | 321 (89) |
| >1-10 | 2 (40) | 17 (9) | 19 (10) | 5 (6) | 7 (8) | 31 (9) |
| >10 | — | 2 (1) | 2 (1) | 3 (3) | 3 (3) | 8 (2) |
| 3- and 6-mo response categories . | Response, n (%) . | |||||
|---|---|---|---|---|---|---|
| Imatinib 400 . | Imatinib 800 . | Imatinib (400 and 800) . | Nilotinib . | Dasatinib . | Overall . | |
| 3-mo cytogenetic response (n = 448) | ||||||
| 0 | 25 (37) | 118 (62) | 143 (55) | 79 (84) | 78 (81) | 300 (67) |
| 35 < 0 | 24 (35) | 55 (29) | 79 (30) | 12 (13) | 13 (13) | 104 (23) |
| >35 | 18 (26) | 18 (9) | 36 (14) | 3 (3) | 5 (5) | 44 (10) |
| 3-mo molecular response (n = 379) | ||||||
| ≤1 | 12 (70) | 133 (78) | 145 (77) | 79 (8) | 76 (79) | 300 (79) |
| >1-10 | 4 (23) | 32 (19) | 36 (19) | 16 (16) | 14 (14) | 66 (17) |
| >10 | 1 (6) | 5 (3) | 6 (3) | 1 (1) | 6 (6) | 13 (3) |
| 6-mo cytogenetic response (n = 424) | ||||||
| 0 | 29 (43) | 154 (84) | 183 (73) | 85 (96) | 79 (91) | 347 (81) |
| 35 < 0 | 27 (40) | 21 (11) | 48 (19) | — | 5 (6) | 53 (12) |
| >35 | 11 (16) | 7 (4) | 18 (7) | 3 (3) | 3 (3) | 24 (7) |
| 6-mo molecular response (n = 360) | ||||||
| ≤1 | 3 (60) | 156 (89) | 159 (88) | 81 (91) | 81 (89) | 321 (89) |
| >1-10 | 2 (40) | 17 (9) | 19 (10) | 5 (6) | 7 (8) | 31 (9) |
| >10 | — | 2 (1) | 2 (1) | 3 (3) | 3 (3) | 8 (2) |
The percentages represent the proportion of patients with respect to the total number of patients in each TKI arm falling into each response category.